Revolutionizing Spinal Cord Injury Recovery with ExoPTEN
Exciting Developments in Spinal Cord Injury Treatment
NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) is making remarkable strides in the treatment of spinal cord injuries with their innovative therapy, ExoPTEN. In a recent preclinical study, significant findings emerged demonstrating that ExoPTEN can effectively target and localize at injury sites even when administered up to seven days post-injury. This extended timing offers an essential window for therapeutic intervention that could maximize recovery potential for numerous patients.
Key Findings from the Preclinical Study
Conducted with a spinal cord compression model, the study revealed that when ExoPTEN is introduced to the body, it has a substantial affinity for the site of injury. This property was evaluated through a series of timed administrations—on day zero (the day of injury), and subsequently on days three, five, and seven. The findings indicated that ExoPTEN displayed a remarkable cumulative presence at the injury, with particularly impressive results seen in cases where treatment was delayed by up to a week.
Implications for Patient Treatment Options
According to Dr. Lior Shaltiel, the company's CEO, these findings could notably expand the patient cohort eligible for treatment. The ability to administer ExoPTEN within a week offers hope for individuals who previously may not have been able to access timely treatment. The implications of this are profound, especially considering the global incidence of spinal cord injuries estimated between 250,000 and 500,000 annually.
Methodology of the Study
The study utilized an advanced In Vivo Imaging System (IVIS) to monitor the behavior of ExoPTEN as it was administered racially to injury-affected rats. The results showed a consistent accumulation of the therapy at the injury site, with evidence of dose-dependent relationships, underscoring the precision and targeted nature of ExoPTEN as a therapeutic agent.
Enhanced Recovery Potential and Clinical Application
These developments not only bolster the belief in ExoPTEN's therapeutic capabilities but also open doors to improved clinical trial designs. The ability to implement flexible treatment regimens will enable healthcare providers to better serve patients suffering from central nervous system injuries, positioning NurExone as a leader in innovative therapies.
About NurExone Biologic Inc.
Established as a frontrunner in the development of exosome-based therapies, NurExone Biologic Inc. is revolutionizing approaches to treating serious health issues stemming from central nervous system injuries. Their key product, ExoPTEN, has shown remarkable efficacy in restoring motor functions in preclinical models and has achieved Orphan Drug Designation from the FDA, pointing to its significance in both clinical and market prospects.
Contact Information for Further Inquiries
For those seeking more information or wishing to discuss potential collaborations, NurExone can be contacted via their dedicated investor relations team:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investor Relations - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investor Relations - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations - US
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
Frequently Asked Questions
What is ExoPTEN and how does it work?
ExoPTEN is an exosome-based therapy developed by NurExone to promote recovery in patients with spinal cord injuries. It is designed to target injury sites effectively.
How long after a spinal cord injury can ExoPTEN be administered?
The study indicates that ExoPTEN can be effectively given up to seven days post-injury, significantly extending the treatment window.
What are the primary benefits of using ExoPTEN?
ExoPTEN enhances targeting at injury sites, improves recovery potential, and allows for more flexible treatment regimens.
What does the FDA designation mean for ExoPTEN?
Getting Orphan Drug Designation from the FDA helps facilitate the development and potential quicker approval of ExoPTEN as a treatment for spinal cord injuries.
Who can I contact for more information about NurExone?
For inquiries, you can reach out directly to Dr. Lior Shaltiel or the investor relations teams across Canada, Germany, or the US through their respective contact details.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.